Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.38.

Several research firms have recently weighed in on AVEO. B. Riley reissued a “buy” rating and set a $5.00 price objective on shares of AVEO Pharmaceuticals in a report on Tuesday, January 16th. BidaskClub raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, began coverage on shares of AVEO Pharmaceuticals in a report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price objective for the company.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVEO. Vanguard Group Inc. raised its holdings in shares of AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after purchasing an additional 1,162,232 shares during the last quarter. Rehmann Capital Advisory Group purchased a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $193,000. Victory Capital Management Inc. purchased a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $164,000. Essex Investment Management Co. LLC purchased a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $550,000. Finally, OxFORD Asset Management LLP purchased a new stake in AVEO Pharmaceuticals during the third quarter valued at approximately $228,000. 50.96% of the stock is owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals (NASDAQ:AVEO) remained flat at $$3.05 on Thursday. 1,899,343 shares of the company traded hands, compared to its average volume of 1,887,461. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $4.24.

WARNING: This piece of content was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/11/analysts-set-aveo-pharmaceuticals-inc-aveo-pt-at-4-38.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.